Twin Tree Management, LP Ionis Pharmaceuticals Inc Call Options Transaction History

Twin Tree Management, LP

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	BUY	$40.06 - $51.86 $3.83 Million - $4.96 Million	95,600 New	95,600 $3.83 Million
Q1 2024 May 09, 2024	BUY	$42.03 - $53.55 $218,556 - $278,460	5,200 New	5,200 $225,000
Q1 2019 May 10, 2019	SELL	$52.92 - $81.17 $5.92 Million - $9.07 Million	-111,800 Reduced 82.57%	23,600 $1.92 Million
Q4 2018 Feb 13, 2019	SELL	$43.37 - $59.54 $975,825 - $1.34 Million	-22,500 Reduced 14.25%	135,400 $7.32 Million
Q3 2018 Nov 09, 2018	SELL	$42.88 - $53.7 $1.34 Million - $1.68 Million	-31,200 Reduced 16.5%	157,900 $8.14 Million
Q2 2018 Aug 08, 2018	SELL	$40.53 - $50.7 $1.78 Million - $2.23 Million	-44,000 Reduced 18.88%	189,100 $7.88 Million
Q1 2018 May 09, 2018	BUY	$44.08 - $55.05 $343,824 - $429,390	7,800 Added 3.46%	233,100 $10.3 Million
Q4 2017 Feb 09, 2018	BUY	$50.3 - $64.39 $3.94 Million - $5.04 Million	78,300 Added 53.27%	225,300 $11.3 Million
Q3 2017 Nov 13, 2017	BUY	$45.56 - $59.57 $6.7 Million - $8.76 Million	147,000	147,000 $7.45 Million

404

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.07B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

Stay updated on Twin Tree Management, LP with notifications on news.